Research programme: PARP inhibitors - BiPar Sciences
Alternative Names: BSI-101; BSI-401Latest Information Update: 04 Nov 2017
At a glance
- Originator BiPar Sciences
- Developer BiPar Sciences; University of Texas M. D. Anderson Cancer Center
- Class Benzopyrans; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pancreatic cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA (PO)
- 22 Oct 2010 Preclinical development is ongoing in USA (PO)
- 07 Nov 2007 Data presented at the 19th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2007) added to the Cancer pharmacodynamics section